Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.

Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.

For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c